

## Disclosure of Shareholdings

### FORM II

**Notification in the case of action in concert or as an organised group and in the case of changes in the composition of those involved and the type of understanding or group pursuant to Art. 10 and Art. 21 SESTO-FINMA**

#### **Addressees and time limits**

Notifications must be submitted to the company and to the competent Disclosure Office in writing within four trading days (Art. 22 para. 1 BEHV-FINMA). Notifications that are submitted by fax or electronically are recognised for the purposes of compliance with time limits. The original document must follow by mail (Art. 7 para. 1 BEHV-FINMA).

#### **Language**

All notifications and applications must be drawn up in English, French or German.

#### **Disclosure forms**

The disclosure forms drawn up by the Disclosure Office of SIX Swiss Exchange are intended to facilitate complete disclosure on the part of those subject to notification obligations. Their use is not mandatory, however.

#### **Address**

SIX Swiss Exchange Ltd.  
Disclosure Office  
Selnaustrasse 30  
P.O. Box 1758  
CH-8021 Zürich

#### **Telephone**

+41 (0)58 399 41 19  
+41 (0)58 399 26 80  
+41 (0)58 399 43 48  
+41 (0)58 399 43 02

#### **Fax**

+41 (0)58 499 2935

#### **e-mail**

offenlegung@six-group.com

## Form II

### Notification in the case of action in concert or as an organised group and in the case of changes in the composition of those involved and the type of understanding or group pursuant to Art. 10 and Art. 21 SESTO-FINMA


#### I. Information on the issuer, persons subject to disclosure obligations, timing and the circumstances triggering the obligation to notify

Name of listed company	1
Evolva Holding SA	
Identity of the individual group members: Surname, first name and place of residence or company name, head office and address of the buyer or seller ( <i>beneficial owner</i> )	2
<p>As notified in the disclosure of shareholdings published on 26 May 2011, the following persons (beneficial owners) have acquired financial instruments with respect to Evolva Holding SA:</p> <ul style="list-style-type: none"> <li>– Jaleh Daie, 1255 Tournament Drive, Hillsborough, CA, 94010, USA</li> <li>– Ganesh Kishore, 11966 Sackston Ridge Drive, St. Louis, MO, 63141, USA</li> <li>– G. Steven Burrill, 41 Rico Way, San Francisco, CA, 94123, USA</li> <li>– Malaysian Life Sciences Capital Fund Ltd., No 36-01, Level 36 Menara Dion, 27, Jalan Sultan Ismail, Kuala Lumpur 50250, Malaysia</li> <li>– Malaysian Technology Development Corporation Sdn. Bhd., Level 8 &amp; 9 Merara Yayasan Tun Razak Jalan Bukit Bintang, Kuala Lumpur 55100, Malaysia</li> </ul>	
In the event of indirect acquisition or indirect sale:	3
<p>Surname, first name and place of residence or company name, head office and address of the <u>direct buyer or seller</u> and/or the other persons concerned, as well as details of the relationship between the beneficial owner and the direct buyer or seller, disclosing the full structure by which control is exercised</p> <p>The financial instruments were acquired by the following common representative of the persons listed under Section I.2 above:</p> <ul style="list-style-type: none"> <li>– Abunda SR, LLC, 409 Illinois Street, San Francisco, California, 94158, USA.</li> </ul> <p>Abunda SR, LLC, aims, amongst others, at representing its members (the individual group members) and facilitating the acquisition by the individual group members of the financial instruments and, at the conversion of the financial instruments, shares in Evolva Holding SA. Abunda SR, LLC, is managed by a board of managers that is appointed by the group members. The management board will, amongst others, exercise the voting rights of the shares in Evolva Holding SA once the financial instruments have been converted.</p>	
Date of the act which creates the obligation to notify	4
8 July 2011	
Date of transfer of equity securities (if different from section 4)	5
See details under Section II hereunder.	
Facts and circumstances triggering the obligation to notify (Art. 21 para. 1 b SESTO-FINMA) (e.g.: acquisition, sale, securities lending and similar transactions pursuant to Art. 14 SESTO-FINMA, exercise or non-exercise of financial instruments pursuant to Art. 15 SESTO-FINMA, changes in the company's registered capital, decisions by a court or public authority, grounds for action in concert or a change to the composition of a group)	
6	
<p>By disclosure of shareholdings published on 26 May 2011, the acquisition of financial instruments in Evolva Holding SA by the persons listed under Section I.2 above, respectively their common representative named under Section I.3 above, was disclosed. On 8 July 2011, Evolva Holding SA has conducted a capital increase by issuing 25'000'000 registered common shares. These shares have been acquired by the persons listed under Section I.2 above, respectively their common</p>	

representative named under Section I.3 above.

As a result of the foregoing, the following changes have occurred as regards the holdings of the persons listed under Section I.2 above, respectively their common representative, disclosed on 19 May 2011 (and published on 26 May 2011):

- As a result of the capital increase of Evolva Holding SA (increase of the number of registered common shares from 139'560'125 by 25'000'000 to 164'560'125) of 8 July 2011, the holdings of the persons listed under Section I.2 above, respectively their common representative named under Section I.3 above, have decreased to the percentages listed under Section II hereunder;
- 25'000'000 registered common shares in Evolva Holding SA have been acquired on 8 July 2011 (the Acquired Shares) in exchange for 25'000'000 rights to acquire such shares (financial instruments);
- A number of 13'387'861 of the Acquired Shares was contributed by the persons listed under Section I.2 above, respectively their common representative named under Section I.3 above, to each a lock-up group and a coordinated sale group (the Groups). These Groups have been disclosed by an individual notification published on [•], whereas the remainder of 11'612'139 Acquired Shares is held outside these Groups and disclosed under Section II.1 hereunder, and
- 222'770 options to purchase shares in Evolva Holding SA have been acquired on 8 July 2011 in exchange for the 222'770 rights to acquire such options.

<p>Type of understanding</p> <p>The individual group members jointly control Abunda SR, LLC, which acquires and holds the equity shares and financial instruments listed under Section II hereunder and, as the conversion into shares in Evolva Holding SA progresses, coordinates the exercise of the voting rights as long as the shares are held by Abunda SR, LLC.</p>	7	<p>Surname, first name, and place of residence of the person responsible for representing all group members</p> <p>- Abunda SR, LLC, 409 Illinois Street, San Francisco, California, 94158, USA</p>	8
<p>Surname, first name, place of residence, telephone and fax numbers of the contact person responsible</p> <p>Dr. Simon Waddington 7 Poplar Drive Kentfield, CA 94904, USA Phone: +1 415-374-0785 swaddington@abundanutrition.com</p>	9	<p>Date and signature</p> <p>11 July 2011</p>  <p>Dr. Simon Waddington</p>	10

## II. Disclosure of purchase positions pursuant to Art. 12 para. 1 a SESTO-FINMA

Equity securities, conversion and share purchase rights (Art. 15 para. 1 a SESTO-FINMA), granted (written) share sale rights (Art. 15 para 1 b SESTO-FINMA) and financial instruments (Art. 15 para. 1 c SESTO-FINMA)

Percentage of voting rights (entire shareholding)	Basis of calculation: total number of voting rights pursuant to the entry in the commercial register (cf. <u>Central Business Names Index</u> )
≤ 14.48 percent	164'560'125 registered common shares

### 1. Equity securities:

Shares	Number	Voting rights <sup>1</sup>	
		Number	Percentage <sup>2</sup>
Regist.	11'612'139	11'612'139	7.06
Bearer			
Total:		<sup>1.1</sup> 11'612'139	<sup>1.2</sup> 7.06

### 2. Financial instruments

Conversion rights, share purchase rights and granted (written) share sale rights that provide or permit actual delivery<sup>3</sup>:

Type of rights	Number of rights	Voting rights conferred		Security ID number (ISIN), if listed on a Swiss stock exchange, or basic terms
		Number	Percentage <sup>2</sup>	
Rights to Acquire Earnout Shares (Share Purchase Rights)	≤ 12'000'000	≤ 12'000'000	≤ 7.29%	To the extent certain events with regard to the Assets of Abunda Nutrition, Inc., set forth in the Agreement and Plan of Merger and Reorganization dated 17 May 2011 between Abunda Nutrition, Inc., <i>et al.</i> , on the one hand, and Evolva Holding SA, on the other hand (the <b>Merger Agreement</b> ) are achieved within a certain time period after the closing of the transaction, the individual group members (beneficial owners) will acquire through their common representative, Abunda SR, LLC, up to a maximum of 12'000'000 shares in Evolva Holding SA in exchange for their 12'000'000 share purchase rights (the <b>Earnout Shares</b> ). A quota of the rights to acquire Earnout Shares is acquired by Abunda SR, LLC, for the account of persons (beneficial owners) that are neither part of the group described under Section I.2 above nor subject to an individual disclosure obligation.
Total:		<sup>2.1</sup> ≤ 12'000'000	<sup>2.2</sup> ≤ 7.29 %	

<sup>1</sup> Whether exercisable or not.

<sup>2</sup> Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (Art. 12 para. 2 SESTO-FINMA).

<sup>3</sup> Whether standardised or not.

Type of rights	Number of rights	Voting rights conferred		Security ID number (ISIN), if listed on a Swiss stock exchange, or basic terms
		Number	Percentage <sup>2</sup>	
Buyer Options (Share Purchase Rights)	222'770	222'770	0.14 %	(e.g.: identity of issuer, underlying, subscription ratio, exercise price, exercise period, exercise type) At the closing of the transaction on 8 July 2011, individual members of the group described under Section 1.2 above acquired 222'770 options to purchase shares in Evolva Holding SA in exchange for their 222'770 rights to acquire such options.
<b>Total:</b>		3.1 222'770	3.2 0.14 %	

**TOTAL SHAREHOLDING:**

Number	Percentage
S1 (=1.1 + 2.1 + 3.1) ≤ 23'834'909	S2 (=1.2 + 2.2 + 3.2) ≤ 14.48 %